{
  "docId": "019de071-4ec1-761e-bce7-779cb9a1fe78",
  "docSlug": "bd64755c9d094dce862ec77cfb2b1978",
  "documentTitle": "TScan Therapeutics | IPO Presentation Deck | 43 slides",
  "authorId": "tscan-therapeutics",
  "authorName": "TScan Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 43,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "other",
  "function": "other",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide highlights a specific partnership deal structure.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de071-4ec1-761e-bce7-779cb9a1fe78/41",
  "deckHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78",
  "deckJsonHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78.json",
  "deckAnchorHref": "/decks/019de071-4ec1-761e-bce7-779cb9a1fe78#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.2,
        "x": 0.75,
        "y": 0.18
      },
      "kind": "image",
      "text": "Hexagonal diagram showing Oncology, Infectious Disease, and Autoimmune Disease",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71713d26-1dec-4f15-a7a3-dff578807fb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.75,
        "y": 0.65
      },
      "kind": "image",
      "text": "Novartis logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1ff6b08-3dd7-4c14-bb2c-0b6ee0002658",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Identifying novel targets and TCRs from patients actively responding to immunotherapy in a select solid tumor indication. Novartis has the option to license and develop TCRs for up to three novel targets. Payments include $20M upfront and $10M research.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f252326-1e30-4e5b-b43a-8334c60b8e72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Partnership with Novartis leveraging TargetScan to discover novel shared targets in solid tumors",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1b72343-0d6d-4a46-9cd6-b0189e5ac734",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Strategic Novartis partnership builds value in oncology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f056117-d738-4c15-b780-e10f7ae4240b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}